Susan Achberger1, Wayne Aldrich1, Raymond Tubbs2, John W Crabb3, Arun D Singh3, Pierre L Triozzi4. 1. Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, United States. 2. Department of Molecular Pathology, Cleveland Clinic Foundation, Cleveland, OH, United States. 3. Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH, United States. 4. Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, United States. Electronic address: triozzp@ccf.org.
Abstract
BACKGROUND: The immune response has been implicated in the control of uveal melanoma progression. Epigenetic mechanisms mediated by specific microRNAs (miRs) regulate immune responses. METHODS: Blood was drawn from six patients with uveal melanoma followed from diagnosis, at which time there was no clinical or radiographic evidence of metastasis, until metastasis manifested. Circulating T cell, natural killer (NK), natural killer T (NKT), and myeloid suppressor cell populations were assessed by flow cytometry. CD3(+), CD15(+), and CD56(+) cells were isolated using immunomagnetic beads. Plasma and cellular levels of immune regulatory miRs were determined by quantitative polymerase chain reaction assays. RESULTS: The development of metastasis was associated with decreases in circulating CD3(-)CD56(dim) NK cells and CD8(+) and double-negative CD3(+)CD56(+) NKT cells. ICOS(+)CD4(+)FoxP3(+) T regulatory cells and CD11b(+)CD14(-)CD15(+) myeloid suppressor cells increased. Plasma levels of miR-20a, 125b, 146a, 155, 181a, and 223 were higher in the study patients at diagnosis compared to controls. Plasma levels of miR-20a, 125b, 146a, 155, and 223 increased, and miR-181a decreased when metastasis manifested. Alterations in immune regulatory miRs were also observed in CD3(+), CD15(+), and CD56(+) cell populations. CONCLUSIONS: The development of metastasis in uveal melanoma is associated with changes in immune effector and regulatory cells consistent with lessening tumor immune surveillance. These changes are associated with changes in plasma and cellular levels of immune regulatory miRs. The results may help guide uveal melanoma immunotherapy and biomarker development.
BACKGROUND: The immune response has been implicated in the control of uveal melanoma progression. Epigenetic mechanisms mediated by specific microRNAs (miRs) regulate immune responses. METHODS: Blood was drawn from six patients with uveal melanoma followed from diagnosis, at which time there was no clinical or radiographic evidence of metastasis, until metastasis manifested. Circulating T cell, natural killer (NK), natural killer T (NKT), and myeloid suppressor cell populations were assessed by flow cytometry. CD3(+), CD15(+), and CD56(+) cells were isolated using immunomagnetic beads. Plasma and cellular levels of immune regulatory miRs were determined by quantitative polymerase chain reaction assays. RESULTS: The development of metastasis was associated with decreases in circulating CD3(-)CD56(dim) NK cells and CD8(+) and double-negative CD3(+)CD56(+) NKT cells. ICOS(+)CD4(+)FoxP3(+) T regulatory cells and CD11b(+)CD14(-)CD15(+) myeloid suppressor cells increased. Plasma levels of miR-20a, 125b, 146a, 155, 181a, and 223 were higher in the study patients at diagnosis compared to controls. Plasma levels of miR-20a, 125b, 146a, 155, and 223 increased, and miR-181a decreased when metastasis manifested. Alterations in immune regulatory miRs were also observed in CD3(+), CD15(+), and CD56(+) cell populations. CONCLUSIONS: The development of metastasis in uveal melanoma is associated with changes in immune effector and regulatory cells consistent with lessening tumor immune surveillance. These changes are associated with changes in plasma and cellular levels of immune regulatory miRs. The results may help guide uveal melanoma immunotherapy and biomarker development.
Authors: Virginia Torres; Pierre Triozzi; Charis Eng; Raymond Tubbs; Lynn Schoenfiled; John W Crabb; Yogen Saunthararajah; Arun D Singh Journal: Future Oncol Date: 2011-01 Impact factor: 3.404
Authors: Jorge Henao-Mejia; Adam Williams; Loyal A Goff; Matthew Staron; Paula Licona-Limón; Susan M Kaech; Maki Nakayama; John L Rinn; Richard A Flavell Journal: Immunity Date: 2013-04-25 Impact factor: 31.745
Authors: Dimitrios Mougiakakos; C Christian Johansson; Eric Trocme; Charlotta All-Ericsson; Mario A Economou; Olle Larsson; Stefan Seregard; Rolf Kiessling Journal: Cancer Date: 2010-05-01 Impact factor: 6.860
Authors: Long V Ly; Aabed Baghat; Mieke Versluis; Ekaterina S Jordanova; Gregorius P M Luyten; Nico van Rooijen; Thorbald van Hall; Pieter A van der Velden; Martine J Jager Journal: J Immunol Date: 2010-08-16 Impact factor: 5.422
Authors: Siwen Hu-Lieskovan; Srabani Bhaumik; Kavita Dhodapkar; Jean-Charles J B Grivel; Sumati Gupta; Brent A Hanks; Sylvia Janetzki; Thomas O Kleen; Yoshinobu Koguchi; Amanda W Lund; Cristina Maccalli; Yolanda D Mahnke; Ruslan D Novosiadly; Senthamil R Selvan; Tasha Sims; Yingdong Zhao; Holden T Maecker Journal: J Immunother Cancer Date: 2020-12 Impact factor: 13.751
Authors: Jason J Luke; Pierre L Triozzi; Kyle C McKenna; Erwin G Van Meir; Jeffrey E Gershenwald; Boris C Bastian; J Silvio Gutkind; Anne M Bowcock; Howard Z Streicher; Poulam M Patel; Takami Sato; Jeffery A Sossman; Mario Sznol; Jack Welch; Magdalena Thurin; Sara Selig; Keith T Flaherty; Richard D Carvajal Journal: Pigment Cell Melanoma Res Date: 2014-09-01 Impact factor: 4.693
Authors: Michelle N Messmer; Colleen S Netherby; Debarati Banik; Scott I Abrams Journal: Cancer Immunol Immunother Date: 2014-11-29 Impact factor: 6.968
Authors: Marco Ragusa; Cristina Barbagallo; Luisa Statello; Rosario Caltabiano; Andrea Russo; Lidia Puzzo; Teresio Avitabile; Antonio Longo; Mario D Toro; Davide Barbagallo; Hadi Valadi; Cinzia Di Pietro; Michele Purrello; Michele Reibaldi Journal: Cancer Biol Ther Date: 2015-05-07 Impact factor: 4.742